Elevance Health, Inc. $ELV Stake Boosted by Brave Warrior Advisors LLC

Brave Warrior Advisors LLC increased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 65.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,834,002 shares of the company’s stock after acquiring an additional 724,349 shares during the period. Elevance Health comprises approximately 13.8% of Brave Warrior Advisors LLC’s portfolio, making the stock its biggest holding. Brave Warrior Advisors LLC’s holdings in Elevance Health were worth $592,603,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ELV. Clearstead Trust LLC lifted its holdings in shares of Elevance Health by 52.9% during the 2nd quarter. Clearstead Trust LLC now owns 263 shares of the company’s stock valued at $102,000 after buying an additional 91 shares during the last quarter. Advisors Capital Management LLC increased its holdings in Elevance Health by 15.2% in the second quarter. Advisors Capital Management LLC now owns 1,331 shares of the company’s stock worth $518,000 after buying an additional 176 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Elevance Health by 4.5% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 55,412 shares of the company’s stock worth $21,553,000 after buying an additional 2,374 shares during the last quarter. Advisory Resource Group bought a new position in Elevance Health during the second quarter valued at approximately $5,147,000. Finally, SG Americas Securities LLC lifted its stake in Elevance Health by 2,978.3% in the second quarter. SG Americas Securities LLC now owns 109,115 shares of the company’s stock valued at $42,441,000 after acquiring an additional 112,906 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

NYSE ELV opened at $291.69 on Friday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The stock has a market capitalization of $64.38 billion, a PE ratio of 11.61, a P/E/G ratio of 1.61 and a beta of 0.51. The stock has a 50-day simple moving average of $338.25 and a 200 day simple moving average of $334.28.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same quarter last year, the firm posted $3.84 EPS. The company’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is currently 27.39%.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Robert W. Baird boosted their target price on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $332.00 price target on shares of Elevance Health in a report on Thursday, January 29th. Morgan Stanley decreased their price objective on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a report on Wednesday, December 17th. Sanford C. Bernstein lowered their target price on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Finally, Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price on the stock. in a report on Tuesday, February 3rd. Twelve analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.